Dr. Tania L. Rivera, M.D.
Rheumatology (Rheumatology Physician)
215 S Hickory St, Suite 114
Escondido, CA 92025
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 170
Licensed in California since 2013, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
CA license A126958 (first issued 2013; current) · NJ license 25MA09188500 · NY license 265348
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Palomar Health Downtown Campus Escondido, CA
Medical groups
- Rheumatology Center of San Diego PC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 170
- Services billed
- 18,794
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, triamcinolone acetonide, preservative free, 1 mg | 1,000 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 482 | 135 |
| Injection of drug or substance under skin or into muscle | 56 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 29 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| Aspiration and/or injection of fluid from large joint | 17 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxychloroquine Sulfate Other prescribers in Escondido, CA | 222 |
| Methotrexate (methotrexate sodium) Other prescribers in Escondido, CA | 135 |
| Prednisone Other prescribers in Escondido, CA | 69 |
| Enbrel Sureclick (etanercept) Other prescribers in Escondido, CA | 69 |
| Folic Acid Other prescribers in Escondido, CA | 48 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Escondido, CA | 45 |
| Leflunomide Other prescribers in Escondido, CA | 44 |
| Alendronate Sodium Other prescribers in Escondido, CA | 36 |
| Evenity (2 Syringes) (romosozumab-aqqg) | 35 |
| Duloxetine Hcl Other prescribers in Escondido, CA | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 149 payments worth $7,358 in total to this clinician.
| Janssen Biotech, Inc. | $2,694 |
|---|---|
| Invivyd Inc | $1,628 |
| AbbVie Inc. | $1,208 |
| UCB, Inc. | $469 |
| Amgen Inc. | $318 |
| Novartis Pharmaceuticals Corporation | $227 |
| Lilly USA, LLC | $149 |
| Radius Health, Inc. | $113 |
| Consulting Fee | $3,953 |
|---|---|
| Food and Beverage | $3,272 |
| Education | $134 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 24, 2025 | Consulting Fee TREMFYA · Immunology | $1,800 |
| Invivyd Inc Oct 23, 2025 | Consulting Fee PEMGARDA · INFECTIOUS DISEASE | $1,628 |
| AbbVie Inc. Oct 10, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $525 |
| Janssen Biotech, Inc. Apr 1, 2025 | Education TREMFYA · Immunology · in-kind | $79.00 |
| Janssen Biotech, Inc. Dec 10, 2025 | Education TREMFYA · Immunology · in-kind | $54.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 6 companies. The companies reported $486,537 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
UCB SA · Completed · NCT06624228 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease
Janssen Research & Development, LLC - A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)
E.r. Squibb & Sons, L.l.c. - A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
E.r. Squibb & Sons, L.l.c. - A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT03915964 - M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)
AbbVie Inc. - A phase 4, multicenter, prospective, open-label study describing the e
GlaxoSmithKline, LLC. - A phase 4, prospective, open-label, single-arm study to assess the effectiveness of tirzepatide after initiation of ixekizumab in adult participants with active psoriatic arthritis and overweight or obesity in clini…
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.